( WEST JEFFERSON N.C.--(BUSINESS WIRE)--...)Next Safety, Inc.'s Innovative Drug Delivery System Will Replace,Cigarettes and Significantly Advance Pulmonary Medication Delivery,Health

WEST JEFFERSON, N.C.--(BUSINESS WIRE)--Jun 15, 2007 - Next Safety, Inc. has identified basic scientific mechanisms that promise to revolutionize pulmonary drug delivery. This proprietary technology uses a stream of purified air to deliver medications deep into the pulmonary system. It is considered superior to other drug delivery systems because it rapidly administers aerosolized drugs to the lining of the lungs at previously unrealized efficiencies. The delivery technique has multiple applications across many therapeutic areas, such as asthma and nicotine replacement. Preliminary findings indicate that the Next Safety device delivers nicotine more efficiently than cigarettes, but without the negative effects of smoke.

According to estimates by the World Health Organizations smoking kills 5 million people globally each year. In 20 years, smoking will kill more than 10 million people per year. Half of the 1.3 billion smokers in the world today (650 million) will die from their habit.

"Our technology will save more lives than have been lost in all the wars in recorded history" - C. Eric Hunter, CEO and Founder of Next Safety, Inc.

"The fundamental nature of this development means that pulmonary delivery for a wide range of drug classes will be vastly improved or enabled," said Tom Stern, MD, assistant professor of medicine in the Department of Internal Medicine at Carolinas Medical Center and member of Next Safety's Medical Advisory Board. "To date laboratory data suggests applications such as childhood asthma or home delivery of medicines previously requiring an IV will be equally benefited. Although further testing is needed, this fundamental breakthrough may eventually be seen as important as the invention of the syringe."

"We've taken a fresh approach to pulmonary drug delivery," said Lyndell Duvall, director of technology & product development for Next Safety, Inc. "By obeying mother
'"/>

Page: 1 2
Related medicine technology :

1. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
2. Bionovos MF101 Shows Positive Safety, Tolerability and Efficacy in Phase 2 Trial
3. Oncolytics Biotech Inc.s Research Collaborators to Present REOLYSIN Clinical Trial Data at ASCO Conference
4. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
5. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
6. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
7. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
8. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
9. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
10. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
11. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology